Mitiglinide

This classification denotes an anti-diabetic agent with the molecular formula C19H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) D86I0XLB13, chemically known as (-)-(2s,3a,7a-cis)-alpha-benzylhexahydro-gamma-oxo-2-isoindolinebutyric acid but more generally known as mitiglinide, which bears US NIH Compound Identifier 3047758. European Medicines Agency schedules Mitiglinide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08999MIG. The term MITIGLINIDE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 12 No. 2 1999, List 40) WHO schedules mitiglinide in its Anatomical Therapeutic Chemical (ATC) Classification. Most nations, for tariff and trade purposes, schedule mitiglinide under HS 29339990 and SITC 51577. As of Q4 2014, MITIGLINIDE remains US FDA's Preferred Term for this commodity. Mitiglinide bears US NLM identifiers UMLS ID C0906166 and NCI Concept Code C81699. SMILES: O=C(N1CC2C(C1)CCCC2)CC(CC1CCCCC1)C(=O)O.